Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Free Cash Flow: 2020-2024

Historic Free Cash Flow for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to -$10.4 million.

  • Therapeutics' Free Cash Flow rose 62.47% to -$10.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$83.4 million, marking a year-over-year increase of 15.03%. This contributed to the annual value of -$83.4 million for FY2024, which is 15.03% up from last year.
  • Therapeutics' Free Cash Flow amounted to -$10.4 million in Q4 2024, which was up 40.81% from -$17.6 million recorded in Q3 2024.
  • In the past 5 years, Therapeutics' Free Cash Flow registered a high of -$6.4 million during Q2 2020, and its lowest value of -$29.0 million during Q2 2023.
  • Over the past 3 years, Therapeutics' median Free Cash Flow value was -$20.7 million (recorded in 2023), while the average stood at -$21.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first slumped by 117.52% in 2021, then surged by 62.47% in 2024.
  • Therapeutics' Free Cash Flow (Quarterly) stood at -$15.5 million in 2020, then tumbled by 35.62% to -$21.1 million in 2021, then decreased by 8.65% to -$22.9 million in 2022, then dropped by 21.50% to -$27.8 million in 2023, then surged by 62.47% to -$10.4 million in 2024.
  • Its Free Cash Flow stands at -$10.4 million for Q4 2024, versus -$17.6 million for Q3 2024 and -$28.2 million for Q2 2024.